MENU
+Compare
ENTA
Stock ticker: NASDAQ
AS OF
Dec 3, 04:59 PM (EDT)
Price
$14.24
Change
+$0.28 (+2.01%)
Capitalization
408.12M

ENTA Enanta Pharmaceuticals Forecast, Technical & Fundamental Analysis

Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases... Show more

Industry: #Biotechnology
ENTA
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for ENTA with price predictions
Nov 28, 2025

ENTA in -5.38% downward trend, declining for three consecutive days on November 19, 2025

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ENTA declined for three days, in of 328 cases, the price declined further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

ENTA broke above its upper Bollinger Band on November 24, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 05, 2025. You may want to consider a long position or call options on ENTA as a result. In of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ENTA just turned positive on November 11, 2025. Looking at past instances where ENTA's MACD turned positive, the stock continued to rise in of 53 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ENTA advanced for three days, in of 283 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 185 cases where ENTA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ENTA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.305) is normal, around the industry mean (27.312). P/E Ratio (0.000) is within average values for comparable stocks, (52.442). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.886). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. P/S Ratio (4.619) is also within normal values, averaging (321.020).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ENTA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

View a ticker or compare two or three
ENTA
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

ENTA is expected to report earnings to fall 10.63% to -77 cents per share on February 09

Enanta Pharmaceuticals ENTA Stock Earnings Reports
Q4'25
Est.
$-0.78
Q3'25
Beat
by $0.14
Q2'25
Missed
by $0.01
Q1'25
Beat
by $0.10
Q4'24
Beat
by $0.22
The last earnings report on November 17 showed earnings per share of -87 cents, beating the estimate of -100 cents. With 104.35K shares outstanding, the current market capitalization sits at 408.12M.
A.I. Advisor
published General Information

General Information

a developer of drugs and other pharmaceuticals products

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
500 Arsenal Street
Phone
+1 617 607-0800
Employees
145
Web
https://www.enanta.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GSPSX34.45N/A
N/A
Goldman Sachs Large Cap Equity Svc
REPIX41.20N/A
N/A
ProFunds Real Estate UltraSector Inv
MSCRX10.47N/A
N/A
Madison Small Cap R6
REEAX16.82N/A
N/A
RBC Emerging Markets Equity A
VLCRX5.97N/A
N/A
Voya Large Cap Value Port R6

ENTA and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ENTA has been loosely correlated with MRUS. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if ENTA jumps, then MRUS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ENTA
1D Price
Change %
ENTA100%
-1.41%
MRUS - ENTA
49%
Loosely correlated
+0.05%
NEVPF - ENTA
44%
Loosely correlated
N/A
ORKA - ENTA
39%
Loosely correlated
+0.56%
AKRO - ENTA
35%
Loosely correlated
+0.12%
ANAB - ENTA
34%
Loosely correlated
-1.09%
More